ST. LOUIS, Aug. 1 /PRNewswire-FirstCall/ -- Sigma-Aldrich is pleased to announce its new ProteoPrep(R)20 LC Column (http://sigma.com/prot20lc) that will simplify biomarker discovery by removing more biological “noise”. With this innovative tool, proteomic researchers will be able to delve deeper into the plasma proteome and save significant time with less fractions to assess in the analysis phase.
Because disease biomarkers are nearly always masked by highly abundant, biologically less significant proteins, the quest to identify and measure them is often confounded. Twenty highly abundant proteins are known to comprise 97% of the human plasma proteome. The ProteoPrep 20 LC Column removes these twenty abundant proteins from human plasma and serum at 98% efficiency, revealing biologically significant proteins previously hidden. Additionally, the remaining significant proteins can be concentrated and effectively magnified 20-fold or greater, allowing researchers to delve deeper than ever before.
“We recognize biomarker discovery as one of the central missions of proteomic research and better drug development to help the human condition. We are proud to provide researchers with yet another best-in-class technology to accelerate their discovery and validation goals. The ProteoPrep 20 LC Column demonstrates our commitment to biomarker discovery and to the greater Proteomic research community,” said Tim Fleming, Director of Global Strategic Marketing, Proteomics, Sigma-Aldrich.
“We particularly like the new higher capacity ProteoPrep 20 LC columns from Sigma-Aldrich and now routinely use these columns in our biomarker discovery research. We can achieve a similar depth of analysis using these columns with less subsequent fractionation, which can reduce mass spectrometer analysis time by as much as 350 hours per plasma proteome. Alternatively, we can achieve greater depth of analysis using a fixed level of fragmentation and mass spectrometer time,” said Dr. David Speicher, Professor and Program Co-Leader of the Molecular and Cellular Oncogenesis Program at the Wistar Institute.
The new, high capacity ProteoPrep 20 LC Column can accommodate a plasma or serum sample of 100 microliters and can be used to deplete a minimum of 100 samples. This effectively enables immunodepletion of more than 10,000 microliters of serum or plasma. The new liquid chromatography version of the ProteoPrep20 technology is compatible with chromatography systems and is therefore more automated. Sigma will also continue to offer the spin column formats.
The ProteoPrep 20 LC Column joins Sigma-Aldrich’s rapidly expanding family of innovative solutions for proteomic research including the Universal Proteomics Standard, Custom AQUA Peptides, the AQUA Peptide Partnership Program, Trypsin Spin Columns, PhosphoProfile 1, PhosDecor(TM) Kit, XPRESS Profiler 725 Antibody Microarray and PepScreen custom libraries.
About Sigma-Aldrich:
Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.
Cautionary Statement:
This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company’s expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company’s operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.
Photo: http://www.newscom.com/cgi-bin/prnh/20070801/AQW023http://www.newscom.com/cgi-bin/prnh/20050215/CGSIGMAALLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comSigma-Aldrich
CONTACT: Sean Battles of Sigma-Aldrich, +1-314-286-7616,sean.battles@sial.com
Web site: http://www.sigma-aldrich.com//
